Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Exactly what I thought would happen has happend. The stock has sold off to 0.60 per share and with no buyers apparently on the horizon this stock could continue to go down. Of course, this should never happen and I must blame current management for the position that the Company finds itself. You can not continue to take an attitude like current management is taking and expect this stock to do something. The new CEO and President should have long ago established value in the Company.
Hi Imcloner. Yes, I did purchase the 100 shares yesterday and I will continue to buy 100 to 500 share lots when I feel the time is ripe. I do not wish to disclose my total holdings, but to me, considering the speculative nature of the stock that I am in, it is substantial. I will continue to purchase shares of CSBR as soon as I see it really begin to move and am convinced that management has its act together. On the other hand, I am also thinking of reducing my holdings if I do not soon see positive action in the rise of the share price of stock
Fred,
I understand your frustration and hope that the market will recognize shortly the true value here.
I questioned you regarding your announced stock purchase of the other day since I know personally who purchased 5,000 of the 5,100 shares traded and since the stock had closed at 45 cents the day before I assume the 100 share block was sold by someone looking to raise the price before they unloaded their shares.
Hi Imcloner:
My expectations for CSBR have always been high for this stock because of Dr. Sidransky. He has performed very well. However, his subordinates have not. Since I have been in it from the inception (about 4 years), I certainly expected much more at this point and I believe so did the original management. My problem is reflected in the share price. On February 22, 2011 the price of these shares were 0.85 per share. Now, a little more than one month later, after announcing one of the best financial results, if not the best, in their history and after a significant contract with one of the leading Biopharmaceutical Companies in this world, their stock is 0.80 per share. That is simply unacceptable, particularly since the C.E.O. and President were brought in to increase the price of the stock. Is this not in and of itself a measure of poor management on the part of the CEO and President? If it is not, I do not know what is. I would assume tht Dr. Sidransky is very upset with this kind of performance. I also allude to my previous comment where the C.E.O was supposed to bring in $5,000,000 of capitalization by January 31, 2011 and in the footnote to the financial statements as of October 31, 2010 it looked like it was a done deal. However, it did not happen. Now, this capitalization is supposed to come by April 30, 2011. We will have to wait and see whether it would materialize. I am now a little too old (71 years of age). However, I wish that I had an opportunity to become the C.F.O. of this Company. I have had experinece before being the Treaurer of a stcok exchange Corporation and during my reign the stock ran from $3 to $10 per share. That was about 41 years ago. I was proactive then in anything I did. Now, I am lucky to be just a little active in anything I do. However, I still own my CPA practice after 40 years. I am not trying, in any way, to brag. I am just trying to analyze the suituiation the way I see it and I see a Company with phenomenol potential, if Dr. Sidransky can get his management team to perform that which they were brought in to do. Incidentally, they still have not hired a CFO and the quarterly financial statements and year end financial statements are due April 30, 2011, I believe.
Fred,
I appreciate your posts and your analyses. I agree that obviously almost no one knows this story yet and that amongst other things is keeping the PPS down (<$5, pink sheets and almost no float being some of the others). As you stated in a later post the CEO (and also the President) are basically working on stock incentive. Their interests should be perfectly aligned with the shareholders (barring any oddball situation where they can sell their stock privately way above what the market offers due to their ability to offer volume). They also need to see appreciation of the share price at some point to recognize gain. (Although their time frame for appreciation may be different than your expectations). I think that share price must be on their minds as well. As far as development of the company I think this last deal shows they are on the right track. Would love to hear of industry wide adaptation of the technology with Champions receiving royalties on any commercialized treatment.
If you don't mind my asking a personal question, when you say "Yes CHM I did buy some more shares today", being that only 5100 shares traded yesterday how many of those are yours?
Hi Beaner:
But that is the problem. There should be a market. I have been following a small company on the pink sheets which is dealing with solar panels. they have no sales as yet. However, they have potential. Their stock ran from 0.69 to $1.20 in a non pump and dump situation during the time that csbr went from .90 to .80. That simply is a case that CSBR management is not telling the story where the story must be told and the other Company is. CSBR is here and now. I maintain that this stock should be valued much higher than it is now and management must be proactive in making that happen. In addition, the new CFO is being compensated with stock for obtaining certain milestones. He was supposed to reach the milestone of a $5,000,000 private placement investment into the Company by January, 2011. Now we are told that it will take place in April. His incentive is incredible. However, his obvious production as far as the stock price is concerned is simply not there so far. I originally thought when he was appointed CEO of the Company that he had sufficient contacts in the investment world to move this stock up. That is one of the reasons that Dr. Sidransky hired him. We are still waiting for results. So far today only 2,500 shares have traded. On this kind of an announcement5 that is not, in any way, good results.
Fred I couldn't agree with you more,this wasn't a shot at your integrity, however sometimes Timing is everything.
With this Company being essentially booted to the pink sheets by means out of their control, there is little to no market right now.
As for a promotion to the big board, we all know how fast this can happen with high growth/margin sectors.
Congrats Fred, you got them to issue the Press Release! The more important thing is that it also shows up as news for Cephalon, so more eyes will see it. Good work, guy.
< Back to Headlines
.Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development
8:58 am ET 03/24/2011- PR Newswire
BALTIMORE, March 24, 2011 /PRNewswire/ -- Champions Biotechnology, Inc. (OTC: CSBR) ("Champions") announced today the signing of a technology collaboration agreement with Cephalon, Inc. in which Champions will conduct low passage Tumorgraft™ studies on two proprietary chemical compounds, CEP-32496, an inhibitor of mutant B-Raf, and CEP-37440, a selective dual ALK-FAK inhibitor, provided by Cephalon to determine the activity or response in potential clinical indications. The results of these studies will be used to inform the future clinical development path of these compounds.
Cephalon will pay Champions an initiation fee of $1,390,000 by April 15, 2011, and will, under certain conditions, also pay Champions various amounts upon achieving certain milestones. Potential milestone payments under the Agreement total $27 million. In addition, under certain conditions, Cephalon will pay Champions royalties on any commercialized products developed under the Agreement.
Guy Malchi, Champion's head of corporate development commented, "This is our largest Translational Oncology Services contract to date and provides us with a great foundation for strong revenue growth for our next fiscal year. We are very excited to be partnering with an innovative company like Cephalon that can utilize our technology to improve the process of oncology drug development. The potential for future milestone and royalty payments in these contracts will allow us to capture a portion of the financial upside our technology generates for our customers. We hope this is just the beginning of a productive and long term partnership between our companies."
Jeffry Vaught, Cephalon's Executive Vice President for R&D said, "Our collaboration with Champions Biotechnology significantly compliments our oncology discovery capabilities by providing wider access to more clinically relevant and predictive pre-clinical oncology models. In addition, Champions' technology platform will enable us to more effectively select the subsets of specific human cancers most likely to respond to our novel targeted therapeutic agents and identify the underlying cancer genotypes associated with drug sensitivity and resistance to chemotherapeutics."
Correction to my previous email. I talked with the person who was President about 3 to 4 years ago, I believe that his name is Mr. Martinelli.
Beaner:
There is a big difference between pumping a stock and getting the stock to fair value. A perfect example of that is chk on the big board. That is, of course, a little different situation. I have been a holder of this stock since inception. I have seen this stock go to $2.15 per share and 0.45 per share this past Tuesday.
Long-Term is in the mind of the beholder. I am 71 so long-term to me could be a month or a year or if really lucky a decade. However, that is besdies the point. The point is that this stock is undervalued now in relationship to its past history and efforts should be made to get the word out. It is in its best position in its history financially and marketing wise and as of 2 days ago the worst position that it has been in the stock. I talked to the CEO a few days ago and he asked me what would be the best way to get the word out. That is an absurdity. He should know and not have to ask. The value of a Company is in the capabilities of its management. I have talked with the previous CFO and he did nt seem that he would leave such a well paying job unless there were some problems. They still have not chosen a replacement CFO. That should be done as soon as possible. I am a CPA. I have worked for 2 of the largest CPA firms in the world and have been in business for myself for over 40 years as a CPA. I was a Treasurer of a stock exchange listed corporation and am very knowledgeable of what it takes to make a Company successful for its shareholders. This stock is undervalued right now. There is very little activity in the stock and considering its performance over the last several months there should be a hightened amount of activity. Look at the share volumes in the past and you will see an awful lot of activity in a period of time when the financials and hopes of the Company was not nearly this good. I continue to believe, based upon my experience which spans 50 years, that this Company is undervalued and that management is not doing a good job in getting the word out. I asked the CEO why he did not have a PR firm and he said that the last one did not do a good job and that they are too expensive. I am sure that there is a decent PR firm out there that they could help and the cost would definitely be worth it to the Company.One more thing. What would happen if someone sells 20,000 shares of the stock at 0.45 per share now as they did a few days ago. How will the stock recoup.there are no other stories I do niot thinkl that would get the stock up. Patinece is fine in the right situation. In this situation, management must do something positive now especially since it is on the pink sheets and that is not something investors in small ciompanies like to see So, I am not after Pumping and Dumping. I am after a good value for the Company based on its current performance and that is not happening. At this rate, it will be a long time before they will be able to be listed on the NASDAQ. I talked with the Past President of this Company last year and he said that its goal was to be listed as soon as possible. He thought that it would be sometime this year. Managenment must move so that this Company will be abhle to reach its true potential for the shareholders. I have been the Company's biggest cheerleader. Go to yahoo-finance and you will see all of the messages that i have written since the Company was formed.
Yes Fred that's a great idea...we could call it "Pump Inc". Relax and read Benz's quotation.....the future is where it's at!!
You can contact him through Linkedin if you have an account.
david sidransky
Professor at Johns Hopkins University
Baltimore, Maryland Area Biotechnology
Yes CHM I did buy some more shares today. The financial results of this Company for the past quarter were simply great. The contract that they just signed with Cephalon was simply fantastic. The PR of the Company is awful. They should be yelling from the highest mountain about the Company and yet they are silent. Even the annoncement today was couched in a filing with the SEC. They should have made a much bigger deal out of this annonucement. You can rest assure that if i were an officer of this Company, the stock would not be languishiong where it is but would be upwards of $1.50. I have had previous experiencde being the Treasurer of an AMEX listed Corporation. I constantly write to the CEO, but am no longer getting any responses. If anyone knows the email of David Sedransky, please let me know so that I can drop him a line. This is a fabuulous Company that no one seems to know about. I think that we can form a PR Company of our own to represent only CSBR and do a better job than is being done currently by management.
I say keep it low till I can scoop up some more cheapies. Wont stay down here for long.
Cream always rises.
Fred, is that you buying those shares this morning?? LOL
I agree that CSBR needs to get it's stuff together regarding PR's. At this point they are treating this as a private company.
Well, if they are trying to stay under the radar, then they are doing a great job.
I agree Fred, something is not right. Let's see what happens when the Name change and new charter is put into place. That should be next week, if not sooner.
Hi again Beaner:
The CEO told me that they are quoted on the pink sheets because they were one of 1,000 Companies that lost their status on the OB classification because it was too expensive for them to carry these Companies without a substantial market maker and apparently CSBR could not find one. I am absolutely flabbergasted that a Company like CSBR with one of their best financial reports is still languishing and worst. IT SIMPLY MAKES NO SENSE. They must get this stock to $4.00 per share for an elongated period of time so that they can be listed on the NASDAQ. This Company needs a good PR Company and I feel the shares would soar if they had one.
Hi Beaner. Cephalon is a major Biopharmaceutical Company with sales approximating $3,000,000,000 per year. This is a very significant occurence. I am still wondering why CSBR did not announce this on March 16, 2011 when the deal was reached. This should propel the stock up considerably. However, it is starting from a very low position at 0.45 per share. Incidentally, the news was only announced through the issuance of an 8-K and does not show up in the news section of the CSBR website.
Yep read the 8k too Fred. It was released after hours, so look for the PR in the morning. 1.3 Million Initation, with a potential of 27 Million if certain milestones are met. Cephalon is a huge Nasdaq100 company.
I can't figure out why they are being quoted on the Pink Sheets though.
THIS BLOWS MY MIND. There is a significant news story that apparently has not hit the wires regarding CSBR. Apparantly they have signed a significant comtract with Cephalon in which they will receive more than 1.5 million dollars by April 11, 2011 and a significant amount later. This story does not appear anywhere except on the Champions Biotechnology web site. Where is management on this? It should have been reported all over the news media. The stock fell to 0.45 per share today when someone sold a little more than 20,000 shares, at the bid price at 3:55 P.M. This should have never happened. I do not understand why management did not make a big splah out of this story. They simply are doing a horrible job in PR and in supporting the value and price of this stock. I was a Treasurer of an AMEX listed Corporation and a story like this would have been all over the news if I were the CFO of CSBR. I have written the C.E.O. asking for an explanation. After you read the article, I am sure that you will agree that now is the time to buy thios stock and not to sell it.
Champions Oncology
Hey, CSBRers...
Interested in your take on the recent notice to shareholders. Looks like the wheels are in motion...
Never Mind Fred, I found the documentation, Interesting.........
I wasn't aware of it either Fred, there has been no disclosure on it. Yahoo has them listed as a Pink Sheet stock, last day of trading as an Otcbb stock was Feb.22nd. Could it be from the resignation of the CFO? I wasn't aware that they are changing there name either.....Where and when did you receive this information?
Regards
Beaner
I believe that the pink sheet situation is only temporary. If one is on the pink sheest there is no necessity to file with the S.E.C. on a quarterly basis. The Company is continuing to do that filing. Therefore, I believe that it is more about the price of the stock than anything else. I am investigating further.
Hi Beaner:
I was not aware that it is moving to the pink sheets. i have not seen an article about that. When is it supposed to move there and why is it happening. It did announce that it is changing its name to Champions Oncology, Inc. Where do I find information regarding that move?
What's you take on the move to the Pink Sheets......hardly a positive step.
If you take a look at the financial statements you will notice that operations contributed a positive cash flow for the 3 months ended 01/31/11. In the previous year and the previous quarters it had always been a negative cash flow. It is important for investors to understand the nuiances and meaning of the financial statements or they will miss the upward move.
The revenue increase was incredible. and if you eliminate the stock situation with the CEO, the Company actually had a profit for the quarter of .02. This is what the Company should be measured by rather than GAP earnings because it shows you a truer comparison. The expense of the stock to the CEO is something that will positively affect tomorrow and not today. This stock is definitely a buy and I can not explain the lack of interest in such positive financial results. I believe that the Company is doing a rotten PR job to let the investors know how far they have come.
Nice increase on revenue.
Things looking up.
CHM- unfortunatelty I really do not have any concrete idea why this stock started soparing at around 2 P.M. today other than to say that i thought I saw a reference in the footnotes to the last financial statements that the Company expected a funding of $5,000,000 by January 31st. I believe that this is the start of the climb that we all have been anticipating. We have been in the valley for three years. It is now time that we enjoy the trip to the top of the mountain. I will see if I can find out anything and if I do, I will let everyone know. Stay tuned.
Fred: Any jungle drums out there?
CSBR up 12% today on decent volume....
Hii CHM760:
No, I have not lost any of my enthusiasm for this stock. On the contrary,, I am much more enthusiastic about this stock today than I was yesterday. I have read the details of the financials, both the numbers and the footnotes. Hidden in these footnotes is information that clearly indicates the enormous size that this Company can become. When it finally explodes, people will think that it is merely an overnight success and will evaporate. That is not true at all. The foundation of this incredible Company is being laid now and it will be a solid foundation from which this Company will grow bigger and bigger and bigger until it is finally acquired. I will soon be buying more of this stock to add to my already substantial holdings. In fact, now is the time to buy while those short term investors are selling their stock for personal tax purposes. I fully expect this stock to go to at least $10.00 per share. Unfortunately, at this time, I can not give you a timetable. However, keep posted and i will keep posting.
Hi Fred. Thanks for the update. I'm glad to see that you haven't lost your enthusiasm for CSBR.
Here's to 2011.
CHM
The financial statements for CSBR for the six months ended October 31, 2010 have been issued and they are very bullish. Sales are up by 13%. For the three months ended October 31, 2010, the Company broke even on a per share basis and for the six months ended October 31, 2010, the Company only lost 0.02 per share. The footnotes indicated that they should receive at least $5,000,000 in financing by January 31, 2011. The Company has four drugs now in various stages of testing that could turn out to be blockbuster drugs for cancer treatment. CSBR is making plans to assure themeselves of success in the future. Many investors do not realize the nature of their spectacular business plan. CSBR licenses drugs from other drug makers and puts the drugs through the testing phase using their tumorgraft ttechnology. If these drugs pass this test and meet certain other criteria, they will then seek a joint venture partner to license the drug from them. The partner could be a major pharmaceutical or biotechnlogy company. It won't be long after that process that biotechnology and pharmaceutical companies realize the phenomenal potential of the Company's technology and the awesome library of drugs that they are building and decide that it would be a wonderful takeover candidate.
Interesting news. Only thing left out is the projected windfall for the company.
The volume today was 86,600 shares which is the largest volume in perhaps two years. Does anyone have any idea why the volume was 28 times the reguklar volume and all of the trades were on the ask side and yet the stock went up only 0.05?
Go to CSBR web site to see the details of the new executives' compensation agreements. Mr. Ackerman gets no salary and Ronnie Morris gets a salary of approximately $13,000 per year. Their incentive is the 5,000,000 options that they have been given to purchase the stock of the Company at 0.875 per share. This is an incredible incentive and, I believe that this stock will begin to move upward very soon.
I believe that the selection of Ackerman as C.E.O. is a fantastic choice for the reasons that I mentioned in my yahoo post. Mr. Ackerman is there basically to incrtease the value of the stock through private financing and his many financial contacts throughout the world. When the time comes for a buyout of CSBR, he will be in the forefront of finding a buyer and negotiating terms. It is sad to me that people do not realize how valuable his position is with this Company and why Mr. Ackerman was put there in the first place. It also seems to me that if you sell your stock now, you are an investment fool. Now is the time to buy and I have been doing and will continue to do that in the future. Mr. Ackerman will not allow the value of the stock to deteriorate. He has too much incentive to make this stock move upward.
Dr Ronnie Morris.....MDVIP
is a national network of physicians who practice proactive, preventive and personalized healthcare, not just the detection and treatment of disease. The national network consists of 376 physicians and over 120,000 patients in 28 states and Washington, D.C. Each physician cares for up to 600 patients rather than the average 2500 patients in a traditional primary care practice. Patients pay an annual membership fee of up to $1800 per year, which includes a comprehensive physical examination and a follow-up wellness plan as well as medical records in CD-ROM format and personalized web sites for each patient. Patients may also be seen for illness as needed. The benefits of a smaller practice are same or next day appointments that start on time as well as unhurried visits and physician availability, 24 hours a day, 7 days a week and enhanced coordination of specialty care.
MDVIP was founded in 2000, and is headquartered in Boca Raton, Florida. Procter & Gamble purchased a share of the company in January 2007, and acquired the company in December 2009.
Management Changes....good or bad?
http://finance.yahoo.com/news/Champions-Biotechnology-prnews-121182070.html?x=0&.v=1
BALTIMORE, Oct. 28 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board:CSBR.ob - News), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced that Mr. Joel Ackerman has joined the management team as the Chief Executive Officer of the Company. In addition, the Company announced that Dr. Ronnie Morris will join the management team as President of the Company; Dr. Morris will concentrate on the development and growth of the personalized medicine business, particularly the Company's Personalized Oncology Services. Both Mr. Ackerman and Dr. Morris will join the company's Board of Directors.
I have written a message regarding the importance of understanding the effect of R&D expenditures on financial statements. The message appears on yahoo-finance-CSBR.OB. It is a significant message that is important to understanding the latest financial results of CSBR.
The financial results for the quarter ended July 31, 2010 were very strong. There was a 66% increase in revenues over the same period in the previous year. The Gross Margin for the quarter ended July 31, 2010 was 71% versus 29% in the quarter ended July 31, 2009. The Financial Statements also showed that the Company is continuing its strong research and development expenditures. The R&D for the quarter ended July 31, 2010 was $919,000 versus $496,000 during the same quarter in the previous fiscal year. If the level of expenditures for R&D during the first quarter of 2011 fiscal year would have been the same as in the same quarter for the previous year, the loss would have been only about $180,000 for the quarter ended July 31, 2010. CSBR shows definite signs of strong growth and I anticipate that fiscal 2011 will reflect that strong growth in its financial statements and its stock price.
This is another very positive step for CSBR. Its reputation is spreading. There may be additional news that may come out before September 15th since between now and then earnings for the first quarter of fiscal 2011 are due to be announced. I am surprised that CSBR did not include this in their announcement on financial results. It leads me to believe that there may be other positive surprises on the announcement of earnings.
Another partnership: this one with Cephalon
Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
7:00 am ET 09/08/2010- PR Newswire
BALTIMORE, Sept. 8 /PRNewswire/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft?cent; platform.
B-Raf, a protein kinase, is a key part of a signaling pathway in the cell that leads to cell proliferation. A mutation in B-Raf is implicated in a wide-range of cancers, including melanoma, colorectal and ovarian cancer.
Under the terms of the agreement, Champions will use its Biomerk Tumorgraft?cent; to test the effectiveness of CEP-32496 in various cancer indications. "We are delighted to add Cephalon to Champions' client list. The preclinical use of our highly-predictive Biomerk Tumorgraft?cent; platform will enable a greater understanding of the clinical potential of CEP-32496," said Elizabeth Bruckheimer, Ph.D., Vice President of Scientific Operations, Champions Biotechnology, Inc.
Bruce Ruggeri, PhD, Senior Director, Oncology Research Drug Discovery at Cephalon stated, "We are excited to work with Champions. These results may be critical in appropriately designing clinical trials to further support the development of this compound."
Hi Fred and Milburn:
The platform sounds pretty interesting, which is why I bought some in 2007. Keeps the stock on my radar screen, but I'm not willing to throw too much into it...yet. Once something starts to heat up, the daily volumes will increase and I feel that will be the time to watch carefully and perhaps throw more money into it.
Fred, I wish you the best and hope the potential you envision for this company, and cancer detection and treatment in general, will come to fruition.
best regards,
CHM
Hi CHM:
There are not too many interested investors and that is quite sad for it is their loss. For all of the reasons that I stated in my message on Yahoo, I am of the belief that this is only the beginning of an exceptional growth period for this Company. Just think of where this Company has come from considering a horrible economy. As long as they can get private investment money, which I believe thay can, this Company will keep growing. It may grow slower than we all desire but that is the nature of the Company until their patented Biomark Tumorgraft Platform helps them discover the next blockbuster cancer killing drug or they are bought out by a another Company who realizes their immense potential. I can not tell you when this will occur. However, I truly believe that it will occur so much so so that I am adding to my already significant stock position in the Company. It will be way too late when the positive announcement comes to add to your position at a reasonable price. Keep the faith and you will be handsomely rewarded. I have been in this stock from its inception and I am 70 years old. If I should no longer be here when the stock soars, my heirs will become very rich. Obviously, a man OF my age should not be investing in A speculative stock unless he is fairly certain of its success. I have done my due diligence. I believe in David Sidransky and his ability to make this Company incredibly successful. The Comopany will be successful because of the quality of its management and its leveraging its Biomark Tumorgraft Platform to produce a library full of cancer killing drugs. Ask yourself, if you had this dreaded disease would you not want a platform that could be used to determine the best drugs for you to take to combat and perhaps eradicate your cancer forever. I know I would. STAY LONG. STAY STRONG. ENJOY THE RIDE AS YOU SEE THE VALUE OF THIS COMPANY GO UP.
Holding since January 2005. Bought then at 5 cents, and I've been adding more on every dip. This one is my lottery ticket. Patience will pay off. Stay long, stay strong. GLTA.
Hi Fred.
Are we the last standing CSBR investors? I gave your Yahoo posts 5 stars, but it sorta looks like we're the only ones left....
Holding since 2007 with a few thousand shares....
CHM
The results for CSBR for the year ended April 30, 2010 were sparkling. I have posted my views on CSBR on Yahoo-Finance CSBR.OB. You will see my opinions including the last one entitled the "Hidden Worth of CSBR."
Followers
|
41
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2378
|
Created
|
11/27/06
|
Type
|
Free
|
Moderators |
CSBR.OB - CHAMPIONS BIOTECHNOLOGY, INC.
Website:http://www.championsbiotechnology.com/
Edgar Filings:
http://www.sec.gov/cgi-bin/browse-edgar?company=Champions+Biotechnology&CIK=0001041771&filenum=&State=&SIC=&owner=include&action=getcompany
2200 Wilson Blvd, Suite 102-316, Arlington, VA 22201
703-526-0400
Primary State of Incorporation: Delaware
James Martell, Chairman/President/CEO
James E. McCollam, Secretary
On February 14, 2007, the Registrant agreed to acquire all of the patent rights underlying pending U.S. Patent Application no. 11/673,519 and corresponding international patent application (PCT/US2006/014449) filed under the Patent Cooperation Treaty (PCT), both entitled “Design and Synthesis of Novel Tubulin Polymerization Inhibitors: Benzoylphenylurea (BPU) Sulfur Analogs.” The acquisition represents the commencement of the Registrant’s strategy to develop a biotechnology business based on therapeutic drug candidates among other possible ventures.
The purchase price for the patent rights consisted of an aggregate of up to 550,000 restricted shares of common stock, of which 300,000 restricted shares were issued upon execution of the acquisition agreement and 250,000 restricted shares are issuable upon the issuance of one or patents based on U.S. Patent Application no. 11/673,519. The Registrant has 27,624,658 issued and outstanding common shares and of those, 19,573,000 are restricted common shares.
On January 5, 2007, the Registrant agreed to issue 7,000,000 shares of common stock toDr. David Sidransky, an individual investor, for an aggregate purchase price of $28,000. These securities were issued pursuant to a privately negotiated transaction without an underwriter in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act.
On January 3, 2007, the Registrant agreed to issue 2,500,000 shares of common stock to Dr. Manuel Hidalgo, an individual investor, for an aggregate purchase price of $10,000. These securities were issued pursuant to a privately negotiated transaction without an underwriter in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act.
David Sidransky, M.D.
http://www.cnn.com/SPECIALS/2001/americasbest/science.medicine/pro.dsidransky.html
David Sidransky, M.D., has served as a director of the ImClone Systems, since January 2004. On June 15, 2005, Dr. Sidransky was named Vice Chairman of the Board of Directors. Dr. Sidransky is the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine. He is a founder of several private biotechnology companies and has served on scientific advisory boards of many private and publicly traded companies, including MedImmune Inc., Telik Inc., Roche, and Amgen Inc. Dr. Sidransky is also a director of Alfacell Inc. He was formerly on the Board of Scientific Counselors at the National Institute of Dental and Craniofacial Research and a member of the Recombinant DNA Advisory Committee at the National Institute of Health. Dr. Sidransky serves on numerous editorial boards and is Senior Editor of Clinical Cancer Research. In addition, he is a Professor of Oncology, Otolaryngology-Head and Neck Surgery, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at Johns Hopkins University and Hospital. Dr. Sidransky is certified in Internal Medicine and Medical Oncology by the American Board of Medicine. He has over 250 peer-reviewed publications, and has contributed more than 40 cancer reviews and chapters and also has numerous issued biotechnology patents. He has been the recipient of many awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award
Link to David Sidransky's patents:
http://www.google.com/patents?client=firefox-a&lr=&q=David+Sidransky&ie=ISO-8859-1&s....
Manuel Hidalgo, M.D., Ph.D.
-Associate Professor of Oncology at the Johns Hopkins Institute.
-M.D.,University Navarra Medical School, Pamplona, Spain
-Ph.D., Infectious Diseases in Cancer, Univeristy Autonoma, Madrid, Spain
-Fellowship (Medical Oncology) University Hospital “12 de Octubre”, Madrid, Spain
-Research Fellow, University Hospital “ 12 de Octubre”, Madrid, Spain
-Clinical Research Fellow, Cancer Therapy and Research Center, San Antonio, TX
-Board Certification in Medical Oncology
-Clinical Interests: Stomach cancer, Colon and rectum cancers, Pancreas cancer, Biliary Tract cancer, Gallbladder cancer.
Dr. Hidalgo is considered a leading researcher in the development of targeted therapies for the treatment of cancer in patients with solid tumors. His research focuses on optimizing the clinical development of novel treatments by measuring target receptor and molecular anomalies, as well as analyzing the biological activity in tumor and normal tissues of patients treated with specific therapies. Dr. Hidalgo is the Principal Investigator in four new clinical studies started within the last year at the Drug Development Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine.
Link to Manuel Hidalgo's patents:
http://www.google.com/patents?client=firefox-a&lr=&q=Manuel+Hidalgo&ie=ISO-8859-1&sp...
OS: 31,624,658 issued and outstanding common shares
Restricted: 23,573,000
Float: 8,051,658
Transfer Agent: Integrity Stock Transfer, Las Vegas, NV 89120
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
News Items and Filings
Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader |
BALTIMORE, Sept. 1 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC:CSBR) (BULLETIN BOARD: CSBR) , a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established yet another agreement with a large biotechnology company for the evaluation of a novel oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform. By maintaining the fundamental genotypic features of the original human tumor along with the stromal components, the Biomerk Tumorgraft preclinical platform enables identification of the most promising development path for a compound in terms of indication, drug combination, and target patient population. The platform also has the potential to identify gene pathways of response and resistance as well as prognostic molecular biomarkers. "We are excited to continue the growth of our impressive client base and begin working with one of the most respected global leaders in the discovery and development of novel therapies," said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "Studies suggest that evaluation of oncology compounds through our Biomerk Tumorgraft platform will lead to more successful and efficient clinical development. The value-added by an optimally targeted, more efficient clinical path can result in cost savings, improved clinical and commercial success and significantly more years of patent life following commercialization." About Champions Biotechnology, Inc. Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that unlike traditional xenografts, these Tumorgrafts closely reflect human cancer biology and their response to drugs is predictive of clinical outcomes in cancer patients. Champions Biotechnology leverages its preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates. As drugs progress through early stage development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care and to companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery. http://www.championsbiotechnology.com/http://www.personalizedcancertreatment.com/
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |